Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
As the American Society for Radiation Oncology gathers for its annual meeting, a radiation oncologist from Roswell Park Comprehensive Cancer Center is highlighting new evidence that a single dose, or “fraction,” of radiation therapy may be as effective as multiple radiotherapy treatments in addressing lung cancer tumours located centrally in the lung.
While stereotactic body radiation therapy (SBRT), a form of radiation therapy often incorporated into the treatment of lung malignancies and other cancers of the organs, is effective and well-tolerated for peripheral tumours located in the outer regions of the lung, the role of single-fraction SBRT in treating central lung tumours is not well-established, says Roswell Park’s Mark Farrugia, MD, PhD, who was invited to share the findings in a talk at ASTRO 2024 today.
“Treatment of central lung tumours can pose more challenges compared to cancers located in the outer portions or periphery of the lungs,” says Dr. Farrugia, Assistant Professor of Oncology and Radiation Medicine at Roswell Park. “We saw in this pilot study that single-fraction stereotactic body radiation therapy demonstrated high rates of tumour control and low toxicity when used to treat central lung tumours.”
“We wondered whether reducing the radiation dose to the organs at risk — even at the expense of controlling the tumour — would lower the risk of toxicity while still achieving acceptable local control. Indeed, this appears to be the case,” says Anurag Singh, MD, Professor of Oncology and Director of Radiation Research at Roswell Park, and senior author of the new study.
Dr. Farrugia is presenting the findings at 1:05 p.m. ET in the Walter E. Washington Convention Center, Room 147, as part of a scientific session (SS 32) dedicated to clinical trials assessing SBRT to treat lung tumours.
For more information, see the study abstract, 285 - A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.